CTRI/2023/07/055457尚未招募2 期
Double Blind Placebo Controlled Clinical Evaluation of Patented Natural Formulation with Special Reference to Menstrual Irregularities of various etiologies and women wellbeing
SARVOTHAM CARE LIMITED0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •i)Females aged between 18 to 45 years.
- •ii)Women with menstrual irregularity and anovulatory cycles, which may be associated with Infertility and PCOS .
- •iii)No past history of renal, hepatic, or any other chronic illness.
- •iv)Normal liver, and renal function tests.
- •v)Patients freely willing and able to provide written informed consent, willing to follow study procedures.
- •vi)Volunteers has no known history of allergy to both placebo and non-placebo group to be noted in CFR.
排除标准
- •i)Any systemic pathologies like tuberculosis, uncontrolled Diabetes mellitus- Type I & suffering from malignant hypertension.
- •ii)Any genetic or congenital anomaly resulting in amenorrhoea and oligomenorrhoea.
- •iii)Any recent medical or surgical illness including malignancies and premature menopause or surgical menopause or secondary longer amenorrhea.
- •iv)Not willing to sign the informed consent and not committed for regular follow ups cooperating the clinical evaluation and having a planned pregnancy during the study process.
研究者
相似试验
进行中（未招募）
不适用
Double Blind Placebo Controlled Clinical Investigation into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients with Severe Pulmonary Arterial HypertensioYHA Class III and IV patients with severe Pulmonary Arterial HypertensioMedDRA version: 14.1Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2004-003236-59-ITnited Therapeutics Corporation220
进行中（未招募）
1 期
Double blind placebo controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension.EUCTR2004-003236-59-BEnited Therapeutics Corporation220
进行中（未招募）
1 期
Double blind placebo controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension.YHA Class III and IV patients with severe Pulmonary Arterial Hypertension (PAH)EUCTR2004-003236-59-GBnited Therapeutics Corporation220
进行中（未招募）
不适用
Double blind placebo controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension.EUCTR2004-003236-59-DEnited Therapeutics Corporation220
进行中（未招募）
不适用
Double blind placebo controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension.EUCTR2004-003236-59-ATnited Therapeutics Corporation220